Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 104

1.

Knowledge management in the era of digital medicine: A programmatic approach to optimize patient care in an academic medical center.

Shellum JL, Nishimura RA, Milliner DS, Harper CM Jr, Noseworthy JH.

Learn Health Syst. 2017 Feb 13;1(2):e10022. doi: 10.1002/lrh2.10022. eCollection 2017 Apr.

2.

Executive Leadership and Physician Well-being: Nine Organizational Strategies to Promote Engagement and Reduce Burnout.

Shanafelt TD, Noseworthy JH.

Mayo Clin Proc. 2017 Jan;92(1):129-146. doi: 10.1016/j.mayocp.2016.10.004. Epub 2016 Nov 18. Review.

PMID:
27871627
3.

Poor early relapse recovery affects onset of progressive disease course in multiple sclerosis.

Novotna M, Paz Soldán MM, Abou Zeid N, Kale N, Tutuncu M, Crusan DJ, Atkinson EJ, Siva A, Keegan BM, Pirko I, Pittock SJ, Lucchinetti CF, Noseworthy JH, Weinshenker BG, Rodriguez M, Kantarci OH.

Neurology. 2015 Aug 25;85(8):722-9. doi: 10.1212/WNL.0000000000001856. Epub 2015 Jul 24. Erratum in: Neurology. 2015 Oct 13;85(15):1355.

4.

What is ahead for Mayo Clinic?

Noseworthy JH.

Mayo Clin Proc. 2014 Apr;89(4):440-3. doi: 10.1016/j.mayocp.2014.02.008. No abstract available.

PMID:
24684871
5.

Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis.

Tutuncu M, Tang J, Zeid NA, Kale N, Crusan DJ, Atkinson EJ, Siva A, Pittock SJ, Pirko I, Keegan BM, Lucchinetti CF, Noseworthy JH, Rodriguez M, Weinshenker BG, Kantarci OH.

Mult Scler. 2013 Feb;19(2):188-98. doi: 10.1177/1352458512451510. Epub 2012 Jun 26.

6.

Three tough acts to follow.

Noseworthy JH.

Neurology. 2011 Dec 6;77(23):2004-5. doi: 10.1212/WNL.0b013e31823b4715. No abstract available.

PMID:
22146920
7.

The Mayo Clinic Value Creation System.

Swensen SJ, Dilling JA, Harper CM Jr, Noseworthy JH.

Am J Med Qual. 2012 Jan-Feb;27(1):58-65. doi: 10.1177/1062860611410966. Epub 2011 Sep 6.

PMID:
21896787
8.

Progress report and a farewell.

Noseworthy JH.

Neurology. 2009 Jul 7;73(1):8-10. doi: 10.1212/WNL.0b013e3181af3354. No abstract available.

PMID:
19564580
9.

Citation and readership metrics: how does Neurology measure up?

Noseworthy JH, Gross RA.

Neurology. 2008 Dec 2;71(23):1846-7. doi: 10.1212/01.wnl.0000338901.48085.5e. No abstract available.

PMID:
19047556
10.

Translating research into treatments.

Noseworthy JH, Gross RA, Engel AG, Johnston KC, Knopman DS, Mink JW, Ransohoff RM, Uitti RJ.

Neurology. 2008 Jul 22;71(4):232-3. doi: 10.1212/01.wnl.0000314830.63429.a1. Epub 2008 Jun 4. No abstract available.

PMID:
18525031
11.

Disability as an outcome in MS clinical trials.

Ebers GC, Heigenhauser L, Daumer M, Lederer C, Noseworthy JH.

Neurology. 2008 Aug 26;71(9):624-31. doi: 10.1212/01.wnl.0000313034.46883.16. Epub 2008 May 14.

PMID:
18480462
12.

How much can we learn from long-term extension trials in multiple sclerosis?

Noseworthy JH.

Neurology. 2006 Sep 26;67(6):930-1. No abstract available.

PMID:
17000954
13.

MRI findings in benign multiple sclerosis are variable.

Pittock SJ, Noseworthy JH, Rodriguez M.

J Neurol. 2007 Apr;254(4):539-41. Epub 2006 Aug 29. No abstract available.

PMID:
16944348
14.

MRI findings of rapidly progressive ophthalmoplegia and blindness in mucormycosis.

Hu WT, Leavitt JA, Moore EJ, Noseworthy JH.

Neurology. 2006 May 23;66(10):E40. No abstract available.

PMID:
16717200
15.

Not every patient with multiple sclerosis should be treated at time of diagnosis.

Pittock SJ, Weinshenker BG, Noseworthy JH, Lucchinetti CF, Keegan M, Wingerchuk DM, Carter J, Shuster E, Rodriguez M.

Arch Neurol. 2006 Apr;63(4):611-4. No abstract available.

PMID:
16606780
16.

A randomized controlled crossover trial of aspirin for fatigue in multiple sclerosis.

Wingerchuk DM, Benarroch EE, O'Brien PC, Keegan BM, Lucchinetti CF, Noseworthy JH, Weinshenker BG, Rodriguez M.

Neurology. 2005 Apr 12;64(7):1267-9.

PMID:
15824361
17.

Natalizumab.

Noseworthy JH, Kirkpatrick P.

Nat Rev Drug Discov. 2005 Feb;4(2):101-2. No abstract available.

PMID:
15756757
18.

Quality of life is favorable for most patients with multiple sclerosis: a population-based cohort study.

Pittock SJ, Mayr WT, McClelland RL, Jorgensen NW, Weigand SD, Noseworthy JH, Rodriguez M.

Arch Neurol. 2004 May;61(5):679-86.

PMID:
15148144
19.

Disability profile of MS did not change over 10 years in a population-based prevalence cohort.

Pittock SJ, Mayr WT, McClelland RL, Jorgensen NW, Weigand SD, Noseworthy JH, Rodriguez M.

Neurology. 2004 Feb 24;62(4):601-6. Review.

PMID:
14981177
20.

Change in MS-related disability in a population-based cohort: a 10-year follow-up study.

Pittock SJ, Mayr WT, McClelland RL, Jorgensen NW, Weigand SD, Noseworthy JH, Weinshenker BG, Rodriguez M.

Neurology. 2004 Jan 13;62(1):51-9.

PMID:
14718697
21.

Incidence and prevalence of multiple sclerosis in Olmsted County, Minnesota, 1985-2000.

Mayr WT, Pittock SJ, McClelland RL, Jorgensen NW, Noseworthy JH, Rodriguez M.

Neurology. 2003 Nov 25;61(10):1373-7.

PMID:
14638958
22.

Management of multiple sclerosis: current trials and future options.

Noseworthy JH.

Curr Opin Neurol. 2003 Jun;16(3):289-97. Review.

PMID:
12858064
23.

Treatment of multiple sclerosis and related disorders: what's new in the past 2 years?

Noseworthy JH.

Clin Neuropharmacol. 2003 Jan-Feb;26(1):28-37. Review. No abstract available.

PMID:
12567162
24.

Randomized controlled trials to assess therapies for multiple sclerosis.

Wingerchuk DM, Noseworthy JH.

Neurology. 2002 Apr 23;58(8 Suppl 4):S40-8. Review.

PMID:
11971125
25.

International consensus statement on the use of disease-modifying agents in multiple sclerosis.

Freedman MS, Blumhardt LD, Brochet B, Comi G, Noseworthy JH, Sandberg-Wollheim M, Soelberg SP; Paris Workshop Group.

Mult Scler. 2002 Feb;8(1):19-23.

PMID:
11936483
26.

The impact of blinding on the results of a randomized, placebo-controlled multiple sclerosis clinical trial. 1994 [classical article].

Noseworthy JH, Ebers GC, Vandervoort MK, Farquhar RE, Yetisir E, Roberts R.

Neurology. 2001 Dec;57(12 Suppl 5):S31-5. No abstract available.

PMID:
11902593
27.

Multiple sclerosis.

Keegan BM, Noseworthy JH.

Annu Rev Med. 2002;53:285-302. Review.

PMID:
11818475
28.

A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis.

Noseworthy JH, O'Brien PC, Petterson TM, Weis J, Stevens L, Peterson WK, Sneve D, Cross SA, Leavitt JA, Auger RG, Weinshenker BG, Dodick DW, Wingerchuk DM, Rodriguez M.

Neurology. 2001 Jun 12;56(11):1514-22.

PMID:
11402108
29.

Use of motion analysis for quantifying movement disorders.

Kaufman KR, Shaughnessy WJ, Noseworthy JH.

Adv Neurol. 2001;87:71-81. Review. No abstract available.

PMID:
11347245
30.

Multiple sclerosis: current pathophysiological concepts.

Wingerchuk DM, Lucchinetti CF, Noseworthy JH.

Lab Invest. 2001 Mar;81(3):263-81. Review.

PMID:
11310820
31.

Relationship of urinary myelin basic protein-like material with cranial magnetic resonance imaging in advanced multiple sclerosis.

Whitaker JN, Wolinsky JS, Narayana PA, Bartolucci AA, Noseworthy JH, Lublin FD, Linde A, Gjörstrup P, Sullivan HC; North American Linomide Investigators.

Arch Neurol. 2001 Jan;58(1):49-54.

PMID:
11176936
32.

IV immunoglobulin does not reverse established weakness in MS.

Noseworthy JH, O'Brien PC, Weinshenker BG, Weis JA, Petterson TM, Erickson BJ, Windebank AJ, Whisnant JP, Stolp-Smith KA, Harper CM Jr, Low PA, Romme LJ, Johnson M, An KN, Rodriguez M.

Neurology. 2000 Oct 24;55(8):1135-43.

PMID:
11071491
33.

Multiple sclerosis.

Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG.

N Engl J Med. 2000 Sep 28;343(13):938-52. Review. No abstract available.

PMID:
11006371
34.

Linomide in relapsing and secondary progressive MS: part II: MRI results. MRI Analysis Center of the University of Texas-Houston, Health Science Center, and the North American Linomide Investigators.

Wolinsky JS, Narayana PA, Noseworthy JH, Lublin FD, Whitaker JN, Linde A, Gjörstrup P, Sullivan HC.

Neurology. 2000 May 9;54(9):1734-41.

PMID:
10802777
35.

Linomide in relapsing and secondary progressive MS: part I: trial design and clinical results. North American Linomide Investigators.

Noseworthy JH, Wolinsky JS, Lublin FD, Whitaker JN, Linde A, Gjorstrup P, Sullivan HC.

Neurology. 2000 May 9;54(9):1726-33.

PMID:
10802775
36.

Brain atrophy as a surrogate marker in MS: faster, simpler, better?

Jagust WJ, Noseworthy JH.

Neurology. 2000 Feb 22;54(4):782-3. No abstract available.

PMID:
10690960
37.

A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease.

Weinshenker BG, O'Brien PC, Petterson TM, Noseworthy JH, Lucchinetti CF, Dodick DW, Pineda AA, Stevens LN, Rodriguez M.

Ann Neurol. 1999 Dec;46(6):878-86.

PMID:
10589540
38.

Treatment of multiple sclerosis: recent trials and future perspectives.

Noseworthy JH, Gold R, Hartung HP.

Curr Opin Neurol. 1999 Jun;12(3):279-93. Review.

PMID:
10499173
39.

Targeting immunotherapy in multiple sclerosis: a near hit and a clear miss.

Schwid SR, Noseworthy JH.

Neurology. 1999 Aug 11;53(3):444-5. No abstract available.

PMID:
10449101
40.

Progress in determining the causes and treatment of multiple sclerosis.

Noseworthy JH.

Nature. 1999 Jun 24;399(6738 Suppl):A40-7. Review.

PMID:
10392579
41.

Acute disseminated encephalomyelitis after accidental injection of a hog vaccine: successful treatment with plasmapheresis.

Dodick DW, Silber MH, Noseworthy JH, Wilbright WA, Rodriguez M.

Mayo Clin Proc. 1998 Dec;73(12):1193-5.

PMID:
9868420
42.

Paraneoplastic encephalomyelitis and seminoma: importance of testicular ultrasonography.

Wingerchuk DM, Noseworthy JH, Kimmel DW.

Neurology. 1998 Nov;51(5):1504-7.

PMID:
9818899
43.

The Mayo Clinic-Canadian Cooperative trial of sulfasalazine in active multiple sclerosis.

Noseworthy JH, O'Brien P, Erickson BJ, Lee D, Sneve D, Ebers GC, Rice GP, Auty A, Hader WJ, Kirk A, Duquette P, Carter J, Francis G, Metz L, Shuster E.

Neurology. 1998 Nov;51(5):1342-52.

PMID:
9818858
44.

Multiple sclerosis clinical trials: old and new challenges.

Noseworthy JH.

Semin Neurol. 1998;18(3):377-88. Review.

PMID:
9817540
45.

Value of magnetic resonance imaging in assessing efficacy in clinical trials of multiple sclerosis therapies.

Erickson BJ, Noseworthy JH.

Mayo Clin Proc. 1997 Nov;72(11):1080-9. Review.

PMID:
9374985
46.

Clinical outcome measures and rating scales in multiple sclerosis trials.

Wingerchuk DM, Noseworthy JH, Weinshenker BG.

Mayo Clin Proc. 1997 Nov;72(11):1070-9. Review.

PMID:
9374984
47.

Rational clinical immunotherapy for multiple sclerosis.

Hunter SF, Weinshenker BG, Carter JL, Noseworthy JH.

Mayo Clin Proc. 1997 Aug;72(8):765-80. Review.

PMID:
9276606
48.

Measurement of treatment efficacy and new trial results in multiple sclerosis.

Noseworthy JH, Miller DH.

Curr Opin Neurol. 1997 Jun;10(3):201-10. Review.

PMID:
9229126
49.

Promotion of endogenous remyelination in multiple sclerosis.

Lucchinetti CF, Noseworthy JH, Rodriguez M.

Mult Scler. 1997 Apr;3(2):71-5. Review.

PMID:
9291156
50.

Interferon beta-1b: latest published results, 1995.

Noseworthy JH.

Mult Scler. 1996 Jul;1(6):313-6.

PMID:
9345406

Supplemental Content

Loading ...
Support Center